PRIOR AUTHORIZATION REQUEST FORM
Dupilumab (Dupixent®), tralokinumab (Adtralza®), upadacitinib (Rinvoq®), abrocitinib (Cibinqo®) / Refractory atopic dermatitis

DECLARATION OF THE INSURED PERSON

Section 1: Information about the plan member and the patient			
Name of plan member	Insurance policy / certificate	Name of employer	
Name of patient	Date of birth (YYYY/MM/DD)	Telephone	
Address (house number and street name)	City/Town	Province	Postal code

Section 2: Other prescription drug insurance policies			
Do you have other prescription drug insurance?		❒ Yes	❒ No
If so, please answer the following:			
What type of plan is it?		❒ Private	❒ Public
Have you ever submitted a claim for this drug to the other insurer?		❒ Yes	❒ No
What is the status of the claim?	❒ Accepted	❒ Refused	❒ Under review
Did this insurer ask you to complete a prior authorization request?		❒ Yes	❒ No
If so, what is the status of the prior authorization request?	❒ Accepted	❒ Refused	❒ Under review

Please enclose acceptance or refusal documents, if applicable

Section 3: Authorization to disclose personal information

I certify that the information in this prior authorization request is complete, accurate and true.

I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l 'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my relevant personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my relevant personal information including and without limitation any medical information and medical evaluations in connection with the processing of this request.

Photocopies of this document have the same value as the original.

Signature of **patient** (parent/legal guardian) _____ Date _____

IMPORTANT :

All correspondence concerning this form will be sent to the address indicated in the participant's file.

Send us this duly completed form by mail or by fax to: 1-855-453-3942.

Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6

ssq.ca

PRIOR AUTHORIZATION REQUEST FORM
Dupilumab (Dupixent®), tralokinumab (Adtralza®), upadacitinib (Rinvoq®), abrocitinib (Cibinqo®) / Refractory atopic dermatitis

DECLARATION OF THE PRESCRIBER

Section 4: Information about the prescriber		
Name of prescriber	Specialty	Licence No.:
Telephone	Fax	
I hereby certify that the information in this request is complete, true and accurate: Signature of **prescriber** _____ Date _____		

Section 5 : Drug covered by the authorization			
Name of drug	Pharmaceutical form	Strength	**Dosage** Dose: _____ Frequency of administration: _____
Type of request	❒ First request Complete section 6		❒ Continuation of treatment Complete section 7 Also complete section 6 if this is the first authorization requested from SSQ

IMPORTANT:

Please do not provide any genetic test results

Section 6 : Clinical information (first request)
Diagnosis ❒ moderate-to-severe chronic atopic dermatitis ❒ Other. Specify : _____
Evaluation BEFORE the start of treatment with the prescription drug Date (YYYY-MM-DD): _____ EASI:_____ **AND** DLQI:_____ Body surface affected (BSA) : ❒ ≥ 10 % ❒ < 10 % Lesions on the face, palms or soles or in the genital area : ❒ Yes ❒ No

Section 6 : Clinical information (first request) (cont'd)		
Summary of previous trials or contraindications		
Drug or other medical treatment	**Reason for discontinuation**	**Duration of treatment**
Corticosteroids topical high power (1) Name : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Corticosteroids topical high power (2) Name : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Calcineurin inhibitor ❒ Pimecrolimus ❒ Tacrolimus ❒ Other. Specify : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Phototherapy Number of treatments: _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Name : _____ Dose : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Name : _____ Dose : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____
Name : _____ Dose : _____	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _____	From _____ to _____

Section 7 : Clinical information (continuation of treatment)

Information necessary to evaluate the response to treatment

The drug covered by the present authorization request was first taken on (YYYY-MM-DD): _____

Please provide the result for the two following evaluations:

Information related to the evaluation	First evaluation	Follow-up evaluation
Date (YYYY-MM-DD)		
EASI		
DLQI		

Please specify if there is a significant improvement of lesions on the face, palms, soles or genital area compared to the pre-treatment assessment:

❒ Yes

❒ No

Section 8 : Additional information